Reduction in the volume of water for ingesting orally disintegrating tablets of solifenacin (Vesicare® OD), and the clinical disintegration time of Vesicare® OD after unit-dose packaging

This publication has 10 references indexed in Scilit:

• The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Ameliorative Effect of Solifenacin Succinate (Vesicare®), a Bladder-Selective Antimuscarinic Agent, on Overactive Bladder Symptoms, Especially Urgency Episodes
  Journal of Pharmacological Sciences, 2010
• Rapidly Disintegrating Tablets Containing Taste Masked Metoclopramide Hydrochloride Prepared by Extrusion-Precipitation Method
  Chemical and Pharmaceutical Bulletin, 2010
• Formulation Design of Taste-Masked Particles, Including Famotidine, for an Oral Fast-Disintegrating Dosage Form
  Chemical and Pharmaceutical Bulletin, 2008
• Epidemiologic survey of lower urinary tract symptoms in Japan
  Urology, 2006
• Solifenacin in Overactive Bladder Syndrome
  Drugs, 2006
• Solifenacin in Overactive Bladder Syndrome
  Drugs & Aging, 2005
• Management of Overactive Bladder
  New England Journal of Medicine, 2004
• Prevalence and burden of overactive bladder in the United States
  World Journal of Urology, 2003
• Development of oral acetaminophen chewable tablets with inhibited bitter taste
  International Journal of Pharmaceutics, 2003
• The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence Society
  Neurourology and Urodynamics, 2002